Investors
Investor Relations
RudaCure is an AI-driven biotech company developing non-opioid therapeutics for pain and sensory diseases. We are preparing for IPO with a proven pipeline and scalable AI platform.
Strategic Roadmap
2026 Milestones
IPO Underwriter Selection & Full-Scale IPO Launch
RCI001 Korea Phase 2 Clinical Trial Entry
RCI002 ODD Designation / Series Investment
RCI002 Global Licensing
Why Invest
The Investment Case
Proven Licensing Track Record
Hanlim Pharma RCI001/RCI001U domestic licensing. French veterinary pharmaceutical licensing completed. Expanding global partnerships.
Diversified Revenue Streams
Human pharmaceuticals, veterinary medicines, API supply, and CRO services for revenue diversification and sustainable growth.
Scalable AI Platform
RuCIA enables rapid candidate identification with significantly reduced cost and development time.
Non-Opioid Market Leadership
Strategic advantage in a regulatory environment where FDA/EMA prioritize non-addictive alternatives.
Company Snapshot
Key Facts
| Founded | 2018 |
| Cumulative Gov't Grants | ~$4M+ |
| Key Licensing | Hanlim Pharma (RCI001/RCI001U), French Vet Pharma (RCI001AH) |
| IPO Preparation | Underwriter Selected (2025) |
| Core Assets | RuCIA Platform + 3 Pipelines |
| Patent Portfolio | Korea / Japan / US |
Strategic Partners
Partners
“We don’t just treat symptoms; we heal the source of sensory signals.”
For investor inquiries, partnership proposals, or IR materials, please contact us.